Top in hem/onc: Healio’s Wordle-like game, CAR T-cell therapy trial

Two years into the COVID-19 pandemic, some light-hearted fun is long overdue for health care providers. Therefore, Healio launched its own Wordle-like game for clinicians. The announcement was the top story in hematology/oncology last week.

The second top story was about Celyad Oncology’s voluntary pause on its clinical trial evaluating CYAD-101, an investigational chimeric antigen receptor (CAR) T-cell therapy. The company said it decided to pause the trial after receiving reports of two patients who died following treatment with CYAD-101.

Read these and more top stories in hematology/oncology below:

Healio launches Wordle-like game with medical T-W-I-S-T

Put your skills to the test on Healio, which has launched its own version of the wildly popular Wordle game — with a fresh take to appeal to its clinical audience. Read more.

CAR T-cell therapy trial paused after two patient deaths

Celyad Oncology placed a voluntary pause on a clinical trial of CYAD-101 after two patients treated with the investigational chimeric antigen receptor T-cell therapy died. Read more.

Limited liability companies: The foundation of asset protection for many physicians

The reality of health care practice in the 21st century is that lawsuits and liability lurk in the background for physicians. Read more.

Cornell start-up to test novel paradigm for cancer drug delivery

A start-up that was co-founded by researchers at Cornell University has initiated the first therapeutic trial evaluating fluorescent silica nanoparticles, known as “Cornell dots,” as a potential treatment for cancer. Read more.

BRCA mutations linked to increased risk for pancreatic, male breast, other cancers

Pathogenic variants in BRCA1 and BRCA2 appeared associated with increased risks for prostate cancer, pancreatic cancer, male breast cancer and possibly stomach cancer, according to research published in Journal of Clinical Oncology. Read more.